Wall Street brokerages expect that Nuvectra Corp (NASDAQ:NVTR) will announce sales of $12.42 million for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Nuvectra’s earnings. The lowest sales estimate is $11.50 million and the highest is $13.34 million. Nuvectra posted sales of $13.15 million during the same quarter last year, which suggests a negative year over year growth rate of 5.6%. The company is scheduled to announce its next quarterly earnings report after the market closes on Wednesday, July 31st.
On average, analysts expect that Nuvectra will report full year sales of $53.75 million for the current financial year, with estimates ranging from $50.50 million to $57.00 million. For the next year, analysts forecast that the business will post sales of $62.68 million, with estimates ranging from $57.10 million to $68.26 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Nuvectra.
Nuvectra (NASDAQ:NVTR) last issued its quarterly earnings results on Wednesday, May 1st. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.18). The business had revenue of $11.13 million during the quarter, compared to analysts’ expectations of $12.76 million. Nuvectra had a negative net margin of 98.77% and a negative return on equity of 62.18%.
NVTR has been the topic of a number of recent research reports. JMP Securities lifted their target price on Qualys from $85.00 to $100.00 and gave the stock a “market outperform” rating in a report on Thursday, May 2nd. Zacks Investment Research lowered ExlService from a “hold” rating to a “sell” rating in a research note on Wednesday, July 10th. Finally, ValuEngine raised Yirendai from a “strong sell” rating to a “sell” rating in a report on Friday, May 3rd. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $15.00.
Shares of NASDAQ NVTR traded up $0.03 during mid-day trading on Friday, hitting $2.06. The company had a trading volume of 251,190 shares, compared to its average volume of 292,148. Nuvectra has a 12 month low of $2.01 and a 12 month high of $25.17. The company has a current ratio of 6.60, a quick ratio of 6.07 and a debt-to-equity ratio of 0.56. The firm has a market cap of $37.92 million, a PE ratio of -0.64 and a beta of 0.74. The firm’s 50 day simple moving average is $3.20.
In other news, President Joseph Paul Hanchin sold 7,900 shares of the stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $3.98, for a total transaction of $31,442.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Benjamin Tranchina acquired 8,500 shares of Nuvectra stock in a transaction dated Wednesday, May 22nd. The shares were acquired at an average price of $4.25 per share, with a total value of $36,125.00. The disclosure for this purchase can be found here. 2.90% of the stock is currently owned by corporate insiders.
Several institutional investors have recently bought and sold shares of NVTR. Edge Wealth Management LLC boosted its stake in Nuvectra by 89.9% in the second quarter. Edge Wealth Management LLC now owns 40,140 shares of the company’s stock valued at $133,000 after acquiring an additional 19,000 shares during the last quarter. Marshall Wace LLP purchased a new position in Nuvectra in the first quarter valued at about $1,155,000. Meitav Dash Investments Ltd. purchased a new position in Nuvectra in the first quarter valued at about $2,377,000. Thompson Siegel & Walmsley LLC purchased a new position in Nuvectra in the first quarter valued at about $64,000. Finally, Rockefeller Capital Management L.P. boosted its stake in Nuvectra by 0.7% in the first quarter. Rockefeller Capital Management L.P. now owns 435,548 shares of the company’s stock valued at $4,795,000 after acquiring an additional 2,968 shares during the last quarter. Institutional investors own 80.36% of the company’s stock.
Nuvectra Company Profile
Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs.
Recommended Story: What is the float in trading stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.